Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). „Clinical study of the selective anxiolytic agent afobazol”. Eksperimental'naia i klinicheskaia farmakologiia64 (2): 15–9. PMID11548440.
Silkina, IV; Gan'shina, TC; Seredin, SB; Mirzoian, RS (2005). „Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon”. Eksperimental'naia i klinicheskaia farmakologiia68 (1): 20–4. PMID15786959.
Seredin, SB; Melkumian, DS; Val'dman, EA; Iarkova, MA; Seredina, TC; Voronin, MV; Lapitskaia, AS (2006). „Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction”. Eksperimental'naia i klinicheskaia farmakologiia69 (3): 3–6. PMID16878488.
Antipova, TA; Sapozhnikova, DS; Bakhtina, LIu; Seredenin, SB (2009). „Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons”. Eksperimental'naia i klinicheskaia farmakologiia72 (1): 12–4. PMID19334503.
Seredenin, SB; Antipova, TA; Voronin, MV; Kurchashova, SY; Kuimov, AN (2009). „Interaction of afobazole with sigma1-receptors”. Bulletin of experimental biology and medicine148 (1): 42–4. PMID19902093.
Medvedev, VE; Trosnova, AP; Dobrovol'skiĭ, AV (2007). „Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov107 (7): 25–9. PMID18379478.
